Table 1 Demographic characteristics, comorbidities and medical conditions of participants initiating RPV or EFV-containing regimens
From: Observational cohort study of rilpivirine (RPV) utilization in Europe
Characteristic | RPV N = 1355 | EFV N = 333 | p-value1 |
|---|---|---|---|
Age | |||
Median (IQR) | 48.0 (40.0–54.0) | 39.0 (32.5–47.0) | < 0.0001 |
Weight (kg)2 | |||
Median (IQR) | 73.8 (65.0–82.4) | 70.2 (64.0–80.0) | 0.1628 |
Gender | |||
Female | 294 (21.7%) | 53 (15.9%) | 0.0193 |
Male | 1061 (78.3%) | 280 (84.1%) | |
Ethnicity | |||
Non-white | 214 (15.8%) | 52 (15.6%) | 0.9364 |
White | 1141 (84.2%) | 281 (84.4%) | |
Geographical Distribution4 | 0.0001 | ||
South | 445 (32.8%) | 70 (21.0%) | |
West Central | 399 (29.4%) | 58 (17.4%) | |
North | 269 (19.9%) | 68 (20.4%) | |
East Central | 214 (15.8%) | 60 (18.0%) | |
East | 28 (2.1%) | 77 (23.1%) | |
Mode of HIV transmission | 0.0001 | ||
MSM | 628 (46.3%) | 116 (34.8%) | |
PWID | 318 (23.5%) | 114 (34.2%) | |
Heterosexual | 316 (23.3%) | 81 (24.3%) | |
Other | 93 (6.9%) | 22 (6.6%) | |
Prior AIDS diagnoses | |||
No | 1036 (76.5%) | 266 (79.9%) | 0.1828 |
Yes | 319 (23.5%) | 67 (20.1%) | |
Prior non-AIDS diagnoses | |||
Cardiovascular disease | 59 (4.4%) | 4 (1.2%) | 0.0065 |
Non-AIDS defining malignancies | 60 (4.4%) | 6 (1.8%) | 0.0267 |
End stage renal disease | 5 (0.4%) | 0 (0.0%) | 0.2669 |
Pancreatitis | 3 (0.2%) | 0 (0.0%) | 0.3901 |
HCV antibody status | |||
Negative | 736 (54.3%) | 127 (38.1%) | < 0.0001 |
Positive | 541 (39.9%) | 161 (48.3%) | |
Unknown | 78 (5.8%) | 45 (13.5%) | |
HBsAg status | |||
Negative | 1133 (83.6%) | 235 (70.6%) | < 0.0001 |
Positive | 58 (4.3%) | 19 (5.7%) | |
Unknown | 164 (12.1%) | 79 (23.7%) | |
Diabetes | |||
No | 638 (47.1%) | 124 (37.2%) | < 0.0001 |
Yes | 91 (6.7%) | 6 (1.8%) | |
Unknown | 626 (46.2%) | 203 (61.0%) | |
Hypertension | |||
No | 768 (56.7%) | 113 (33.9%) | < .0001 |
Yes | 348 (25.7%) | 48 (14.4%) | |
Unknown | 239 (17.6%) | 172 (51.7%) | |
eGFR (mL/1.73m2) | |||
Median (IQR) | 99.2 (84.2–108.3) | 106.9 (96.0–115.1) | < 0.0001 |
CD4 cell count (/mm3) | |||
Median (IQR) | 566.0 (388.0–770.0) | 305.5 (151.5–486.0) | < 0.0001 |
CD4 cell count nadir (/mm3) | |||
Median (IQR) | 169.0 (35.0–283.0) | 224.0 (76.0–330.0) | < 0.0001 |
HIV viral load (log10 copies/ml) | |||
Median (IQR) | 1.59 (1.28–1.69) | 4.05 (1.60–5.11) | < 0.0001 |
Time enrolled in EuroSIDA (months) | |||
Median (IQR) | 140.8 (69.4–209.7) | 21.4 (1.3–89.2) | < 0.0001 |